Kinetic, spectroscopic and thermodynamic characterization of the Mycobacterium tuberculosis adrenodoxin reductase homologue FprA.

The genome sequence of the pathogenic bacterium Mycobacterium tuberculosis revealed numerous cytochrome P450 enzymes, which require accessory redox enzymes for catalytic function (ferredoxin reductase and ferredoxin). The most likely ferredoxin reductase is encoded by fprA, and its structure resembles eukaryotic adrenodoxin reductases. We have cloned, expressed and purified the flavoenzyme product of the fprA gene in Escherichia coli. FprA reduces various electron acceptors using either NADPH or NADH as the electron donor, but discriminates in favour of NADPH (apparent K (m) for NADH=50.6+/-3.1 microM; NADPH=4.1+/-0.3 microM from ferricyanide reduction experiments). Stopped-flow studies of reduction of the FprA FAD by NADPH demonstrate increased flavin reduction rate at low NADPH concentration (<200 microM), consistent with the presence of a second, kinetically distinct and inhibitory, pyridine nucleotide-binding site, similar to that identified in human cytochrome P450 reductase [Gutierrez, Lian, Wolf, Scrutton and Roberts (2001) Biochemistry 40, 1964-1975]. Flavin reduction by NADH is slower than with NADPH and displays hyperbolic dependence on NADH concentration [maximal reduction rate ( k (red))=25.4+/-0.7 s(-1), apparent K (d)=42.9+/-4.6 microM]. Flavin reoxidation by molecular oxygen is more rapid for NADH-reduced enzyme. Reductive titrations show that the enzyme forms a species with spectral characteristics typical of a neutral (blue) FAD semiquinone only on reduction with NADPH, consistent with EPR studies. The second order dependence of semiquinone formation on the concentration of FprA indicates a disproportionation reaction involving oxidized and two-electron-reduced FprA. Titration of FprA with dithionite converts oxidized FAD into the hydroquinone form; the flavin semiquinone is not populated under these conditions. The midpoint reduction potential for the two electron couple is -235+/-5 mV (versus the normal hydrogen electrode), similar to that for adrenodoxin reductase (-274 mV). Our data provide a thermodynamic and transient kinetic framework for catalysis by FprA, and complement recent spectrophotometric and steady-state studies of the enzyme [Fischer, Raimondi, Aliverti and Zanetti (2002) Eur. J. Biochem. 269, 3005-3013].

[1]  D. Young,et al.  Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. , 1993, Trends in microbiology.

[2]  F. Studier,et al.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. , 1986, Journal of molecular biology.

[3]  J. Lambeth,et al.  Adrenodoxin reductase. Properties of the complexes of reduced enzyme with NADP+ and NADPH. , 1976, The Journal of biological chemistry.

[4]  T. Poulos,et al.  Redox control of the catalytic cycle of flavocytochrome P-450 BM3. , 1997, Biochemistry.

[5]  M. Daffé,et al.  The envelope layers of mycobacteria with reference to their pathogenicity. , 1998, Advances in microbial physiology.

[6]  Claudia S Maier,et al.  A covalent modification of NADP+ revealed by the atomic resolution structure of FprA, a Mycobacterium tuberculosis oxidoreductase. , 2002, Biochemistry.

[7]  R. Feyereisen,et al.  Interaction of NADP(H) with oxidized and reduced P450 reductase during catalysis. Studies with nucleotide analogues. , 2000, Biochemistry.

[8]  J. I. Pedersen,et al.  Purification of NADPH-ferredoxin reductase from rat liver mitochondria. , 1978, Biochimica et biophysica acta.

[9]  S. Takemori,et al.  The purification and properties of NADPH‐adrenodoxin reductase from bovine adrenocortical mitochondria , 1972, FEBS letters.

[10]  M. Waterman,et al.  Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Locht,et al.  Activation of the pro-drug ethionamide is regulated in mycobacteria. , 2000, The Journal of biological chemistry.

[12]  J. I. Pedersen,et al.  Purification of NADPH-ferrodoxin reductase from rat liver mitochondria , 1978 .

[13]  G. Schulz,et al.  Crystal structures of adrenodoxin reductase in complex with NADP+ and NADPH suggesting a mechanism for the electron transfer of an enzyme family. , 2000, Biochemistry.

[14]  N. Scrutton,et al.  Expression and thermodynamic characterisation of the Mycobacterium tuberculosis adrenodoxin reductase homologue FprA , 2002 .

[15]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[16]  V. Massey,et al.  Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. , 1975, The Journal of biological chemistry.

[17]  R. Baxter,et al.  Characterisation of flavodoxin NADP+ oxidoreductase and flavodoxin; key components of electron transfer in Escherichia coli. , 1998, European journal of biochemistry.

[18]  B. Barrell,et al.  Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2) , 2002, Nature.

[19]  N. Scrutton,et al.  Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains. , 2001, Biochemistry.

[20]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[21]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[22]  Malcolm D. Walkinshaw,et al.  Atomic Structure of Mycobacterium tuberculosis CYP121 to 1.06 Å Reveals Novel Features of Cytochrome P450* , 2003, The Journal of Biological Chemistry.

[23]  T. Shimada,et al.  Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  D. Tew Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. , 1993, Biochemistry.

[25]  A. Munro,et al.  Determination of the redox properties of human NADPH-cytochrome P450 reductase. , 2001, Biochemistry.

[26]  N. Scrutton,et al.  Stopped-flow kinetic studies of electron transfer in the reductase domain of neuronal nitric oxide synthase: re-evaluation of the kinetic mechanism reveals new enzyme intermediates and variation with cytochrome P450 reductase. , 2002, The Biochemical journal.

[27]  A. Munro,et al.  Fluorescence analysis of flavoproteins. , 1999, Methods in molecular biology.

[28]  U. Heinemann,et al.  Adrenodoxin: Structure, stability, and electron transfer properties , 2000, Proteins.

[29]  N. C. Price,et al.  Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis. , 2002, Journal of inorganic biochemistry.

[30]  T. Ost,et al.  Phenylalanine 393 exerts thermodynamic control over the heme of flavocytochrome P450 BM3. , 2001, Biochemistry.

[31]  P. Ortiz de Montellano,et al.  Active-site topology of bovine cholesterol side-chain cleavage cytochrome P450 (P450scc) and evidence for interaction of tyrosine 94 with the side chain of cholesterol. , 1995, Archives of biochemistry and biophysics.

[32]  S K Chapman,et al.  Probing the NADPH-binding site of Escherichia coli flavodoxin oxidoreductase. , 2000, The Biochemical journal.

[33]  P. Dutton Redox potentiometry: determination of midpoint potentials of oxidation-reduction components of biological electron-transfer systems. , 1978, Methods in enzymology.

[34]  S. Fujii,et al.  The semiquinone state of NADPH-adrenodoxin oxidoreductase in the course of anaerobic reduction with NADPH. , 1986, Journal of biochemistry.

[35]  H. Hori,et al.  Adrenodoxin-cytochrome P450scc interaction as revealed by EPR spectroscopy: comparison with the putidaredoxin-cytochrome P450cam system. , 2001, Journal of biochemistry.

[36]  Lung Disease,et al.  Anti-tuberculosis drug resistance in the world : the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance , 1997 .

[37]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  N. Scrutton,et al.  Relaxation kinetics of cytochrome P450 reductase: internal electron transfer is limited by conformational change and regulated by coenzyme binding. , 2002, Biochemistry.

[39]  G. Zanetti,et al.  Mycobacterium tuberculosis FprA, a novel bacterial NADPH-ferredoxin reductase. , 2002, European journal of biochemistry.

[40]  A. Munro,et al.  Bacterial cytochromes P‐450 , 1996, Molecular microbiology.

[41]  Gleb Bourenkov,et al.  Adrenodoxin Reductase-Adrenodoxin Complex Structure Suggests Electron Transfer Path in Steroid Biosynthesis* , 2001, The Journal of Biological Chemistry.

[42]  S. Daff,et al.  Calmodulin Activates Electron Transfer through Neuronal Nitric-oxide Synthase Reductase Domain by Releasing an NADPH-dependent Conformational Lock* , 2002, The Journal of Biological Chemistry.